Danish pharmaceutical firm Lundbeck has appointed Jens Peter Balling and Iman Barilero as vice presidents in its research and development organisation as part of the company's ongoing strengthening of regulatory processes.
The new appointments have been made following the consolidation of Lundbeck's research and development activities into one organisation. One result of this consolidation is the creation of a new unit for regulatory product support, patient safety and quality assurance of clinical research.
Jens Peter Balling has been appointed as vice president of the new unit.
Iman Barilero
The organisation for regulatory development and strategy, which is increasingly important for Lundbeck, has also been strengthened with the appointment of Iman Barilero as vice president, who takes responsibility for increasing Lundbeck's efforts to build cooperation and dialogue with national and international regulatory authorities.
Jens Peter Balling joined Lundbeck in 2006 as divisional director of global pharmacovigilance. He has many years of drug safety experience from the Danish pharmaceutical industry, where he previously worked for Novo Nordisk and Nycomed.
Iman Barilero joined Lundbeck in 2007, when she started as divisional director of regulatory development, strategy and policy. She has extensive international experience from several years at Hoffmann-La Roche and Johnson & Johnson.
